MX2021013911A - Tratamiento con lasofoxifeno del cancer de mama. - Google Patents

Tratamiento con lasofoxifeno del cancer de mama.

Info

Publication number
MX2021013911A
MX2021013911A MX2021013911A MX2021013911A MX2021013911A MX 2021013911 A MX2021013911 A MX 2021013911A MX 2021013911 A MX2021013911 A MX 2021013911A MX 2021013911 A MX2021013911 A MX 2021013911A MX 2021013911 A MX2021013911 A MX 2021013911A
Authority
MX
Mexico
Prior art keywords
sup
breast cancer
lasofoxifene
treatment
estrogen receptor
Prior art date
Application number
MX2021013911A
Other languages
English (en)
Inventor
Kaitlyn Andreano
Donald P Mcdonnell
Stephanie L Gaillard
Ching-Yi Chang
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of MX2021013911A publication Critical patent/MX2021013911A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

La descripción proporciona métodos para el tratamiento del cáncer positivo en el receptor de estrógeno (ER+) en mujeres con una cantidad efectiva de lasofoxifeno, una sal farmacéuticamente aceptable del mismo, o un profármaco del mismo. La descripción también incluye la detección de mutaciones del gen Receptor de Estrógeno 1 (ESR1) que lleva a resistencia endocrina y tratamiento de cánceres ER+ con resistencia endocrina.
MX2021013911A 2016-10-11 2019-04-10 Tratamiento con lasofoxifeno del cancer de mama. MX2021013911A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662406859P 2016-10-11 2016-10-11
US201762457759P 2017-02-10 2017-02-10
US201762502299P 2017-05-05 2017-05-05

Publications (1)

Publication Number Publication Date
MX2021013911A true MX2021013911A (es) 2022-01-18

Family

ID=60186386

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004184A MX2019004184A (es) 2016-10-11 2017-10-10 Tratamiento con lasofoxifeno del cancer de mama.
MX2021013911A MX2021013911A (es) 2016-10-11 2019-04-10 Tratamiento con lasofoxifeno del cancer de mama.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019004184A MX2019004184A (es) 2016-10-11 2017-10-10 Tratamiento con lasofoxifeno del cancer de mama.

Country Status (20)

Country Link
US (5) US20180098963A1 (es)
EP (2) EP3525774B1 (es)
JP (4) JP6892151B2 (es)
KR (5) KR102623130B1 (es)
CN (3) CN112353796A (es)
AU (2) AU2017360365B2 (es)
BR (1) BR112019007254A2 (es)
CA (1) CA3040266A1 (es)
DK (1) DK3525774T3 (es)
ES (1) ES2909576T3 (es)
IL (2) IL284875B (es)
MX (2) MX2019004184A (es)
NZ (1) NZ752443A (es)
PL (1) PL3525774T3 (es)
PT (1) PT3525774T (es)
RU (1) RU2019114079A (es)
SG (2) SG10201913951YA (es)
TW (2) TWI729227B (es)
WO (2) WO2018093484A1 (es)
ZA (1) ZA201902454B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
US20230381138A1 (en) * 2022-05-25 2023-11-30 Sermonix Pharmaceuticals, Inc. Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
CA2335361A1 (en) 1998-06-19 1999-12-23 Senju Pharmaceutical Co., Ltd. Medicament for reducing side effects of adrenocortical hormones
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
KR20020073566A (ko) 2000-01-28 2002-09-27 앙도르쉐르슈 인코포레이티드 에스트로겐과 배합된 선택적인 에스트로겐 수용체 조절자
DE10039199A1 (de) 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
AU2002235348A1 (en) 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
KR100636953B1 (ko) 2002-03-28 2006-10-19 화이자 프로덕츠 인코포레이티드 정제된 라소폭시펜 및 재결정화에 의한 라세미라소폭시펜의 정제 방법
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20110015134A1 (en) 2007-04-16 2011-01-20 Retsky Michael W Method of treatment for early stage cancer
CZ2007373A3 (cs) 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
WO2009126662A1 (en) 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
EP2239570A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for determining the estrogen receptor status of breast cancer
US20130253035A1 (en) 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
US20120052508A1 (en) * 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies
MX2013010379A (es) 2011-03-11 2014-03-27 Merrimack Pharmaceuticals Inc Uso de inhibidores de receptores de la familia egfr en el tratamiento de canceres de mama refractarios a hormonas.
WO2012158657A1 (en) 2011-05-18 2012-11-22 Merck Sharp & Dohme Corp. Therapeutic anti-igf1r combinations
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
MD20140054A2 (ro) 2011-12-16 2014-10-31 Olema Pharmaceuticals, Inc. Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US9204286B1 (en) 2013-03-15 2015-12-01 Sprint Communications Company L.P. System and method of branding and labeling a mobile device
SG11201607339VA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
WO2015136016A2 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
EP3834824A1 (en) 2014-03-28 2021-06-16 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
KR20190025733A (ko) 2014-11-07 2019-03-11 리폭센 테크놀로지즈 리미티드 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물
AU2016247674A1 (en) 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
IL307981A (en) * 2015-04-29 2023-12-01 Radius Pharmaceuticals Inc Cancer treatment methods
WO2018071437A1 (en) 2016-10-11 2018-04-19 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
EP3568132A4 (en) 2017-01-10 2020-09-09 Wang, Wei MODULATION BY LASOFOXIFEN OF EESTROGENIC SIGNALS OF MEMBRANARY ORIGIN AND METHODS FOR THE TREATMENT OF TUMORS

Also Published As

Publication number Publication date
JP7247241B2 (ja) 2023-03-28
AU2017360365A1 (en) 2019-05-02
IL265938B (en) 2021-08-31
MX2019004184A (es) 2019-09-27
BR112019007254A2 (pt) 2019-07-02
KR102462433B1 (ko) 2022-11-03
ZA201902454B (en) 2022-09-28
KR102531354B1 (ko) 2023-05-11
ES2909576T3 (es) 2022-05-09
US20190151286A1 (en) 2019-05-23
TW202313005A (zh) 2023-04-01
EP3525774A1 (en) 2019-08-21
KR20210096316A (ko) 2021-08-04
US10905659B2 (en) 2021-02-02
US20180221335A1 (en) 2018-08-09
SG10201913951YA (en) 2020-03-30
US20180098963A1 (en) 2018-04-12
JP7418052B2 (ja) 2024-01-19
CN110099680B (zh) 2021-02-05
WO2018071440A1 (en) 2018-04-19
WO2018093484A1 (en) 2018-05-24
AU2017360365B2 (en) 2022-08-04
DK3525774T3 (da) 2022-03-14
JP2024026527A (ja) 2024-02-28
JP2019529581A (ja) 2019-10-17
KR20240007720A (ko) 2024-01-16
RU2019114079A3 (es) 2021-07-23
JP2021073316A (ja) 2021-05-13
US20230233490A1 (en) 2023-07-27
CN112933082A (zh) 2021-06-11
EP4035662A1 (en) 2022-08-03
IL284875A (en) 2021-08-31
TW201817422A (zh) 2018-05-16
CN110099680A (zh) 2019-08-06
US20210361596A1 (en) 2021-11-25
IL284875B (en) 2022-07-01
KR102285453B1 (ko) 2021-08-05
KR102623130B1 (ko) 2024-01-10
JP2023033415A (ja) 2023-03-10
CN112353796A (zh) 2021-02-12
TWI790672B (zh) 2023-01-21
KR20220151017A (ko) 2022-11-11
SG11201903236SA (en) 2019-05-30
KR20190092377A (ko) 2019-08-07
TW202137980A (zh) 2021-10-16
US20190231718A1 (en) 2019-08-01
JP6892151B2 (ja) 2021-06-23
US10258604B2 (en) 2019-04-16
PL3525774T3 (pl) 2022-04-25
KR20230042390A (ko) 2023-03-28
RU2019114079A (ru) 2020-11-13
AU2022246480A1 (en) 2022-12-08
IL265938A (en) 2019-05-30
PT3525774T (pt) 2022-03-30
EP3525774B1 (en) 2021-12-29
CA3040266A1 (en) 2018-05-24
NZ752443A (en) 2022-11-25
TWI729227B (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
MX2021013911A (es) Tratamiento con lasofoxifeno del cancer de mama.
AU2017362418B2 (en) Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
MX2016011698A (es) Metodos y composiciones para modular mutantes de receptor de estrogeno.
ZA202306801B (en) Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
TW201613635A (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
PH12016502354A1 (en) Pharmaceutical composition
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
AU2019416117B2 (en) CSF1R inhibitors for use in treating cancer
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MY189713A (en) Duocarmycin adcs for use in treatment of endometrial cancer
AU2024202398A1 (en) Inhibition of SMARCA2 for treatment of cancer
IL290789A (en) Methods for the treatment of breast cancer with a history of tetrahydronaphthalene as estrogen receptor antagonists
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
IL273782A (en) Compositions of cells and bacteria for the treatment of colon cancer and methods for evaluating prognosis for these patients
MX2022007678A (es) Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
IL276748A (en) Methods for the detection and treatment of prostate cancer
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
EP3684420A4 (en) METHOD OF TREATMENT FOR TRIPLE NEGATIVE BREAST CANCER
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
IL280830A (en) Bracelets for use in cancer treatment methods
MY194488A (en) Syd985 treatment of t-dm1 refractory cancer patients
SG11202007005UA (en) Use of crassocephalum rabens extract in the treatment of breast cancer
NZ742470A (en) Combination therapy for cancer
Dixon et al. In regard to Moran et al